Opko Embarks On Transition To Profitability With Discount Buy
Executive Summary
The life sciences company picks up Transition Therapeutics in an all-stock deal that fleshes out its pipeline.
You may also be interested in...
The Frost Factor: An M&A Leader's Standout Strategy For Opko Health
With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.
Another Pfizer deal: Opko's once-weekly growth hormone
The latest transaction in Pfizer's year-end dealmaking flurry gives the company an exclusive global license for Opko Health's once-weekly human growth hormone (hGH) candidate Lagova (hGH-CTP), which complements the big pharma's once-daily growth hormone Genotropin (somatropin).